Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Teva Pharmaceutical Industries ADR (NY: TEVA ) 13.01 -0.00 (-0.00%) Streaming Delayed Price Updated: 3:29 PM EDT, Apr 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 5,452,438 Open 12.98 Bid (Size) 13.00 (93) Ask (Size) 13.01 (25) Prev. Close 13.01 Today's Range 12.86 - 13.09 52wk Range 7.085 - 14.46 Shares Outstanding 1,110,352,397 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz April 22, 2024 "Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact." Via Benzinga Topics Intellectual Property Exposures Intellectual Property Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23 April 17, 2024 The Israel-Hamas War has only adversely affected the stock returns of 6 of the 15 small cap Israeli- domiciled companies listed on U.S. exchanges but, In total, their returns have exceeded those of... Via Talk Markets Topics Stocks Exposures US Equities Performance YTD +21.93% +21.93% 1 Month -7.47% -7.47% 3 Month +8.51% +8.51% 6 Month +58.85% +58.85% 1 Year +55.81% +55.81% More News Read More Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire 8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know March 08, 2024 Via Benzinga Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Alvotech Via GlobeNewswire Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 April 09, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead April 08, 2024 Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 April 06, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate April 04, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire 3 No-Brainer Stocks to Buy With $600 Right Now April 03, 2024 Via The Motley Fool Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement April 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In' March 25, 2024 Via Benzinga Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month March 21, 2024 Via Benzinga The Generic Drugs Antitrust Case March 16, 2024 Via Talk Markets Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal March 02, 2024 Via Talk Markets Drug Maker Organon Stock Scores Relative Strength Upgrade February 28, 2024 Via Investor's Business Daily Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session February 26, 2024 Via Benzinga Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000? February 26, 2024 Via InvestorPlace Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock February 26, 2024 Via InvestorPlace TEVA Stock Pops 4% as Teva Receives FDA Approval February 26, 2024 Via InvestorPlace Exposures Product Safety Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? February 26, 2024 Via Benzinga Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session February 26, 2024 Via Benzinga Topics Stocks Exposures US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.